Further studies have shown that application of a TLR7 agonist (Imiquimod) to the skin of humans and mice can initiate psoriatic lesions that are dramatically worsened on an IL-36RA null background, whereas imiquimod-induced psoriasis is completely abolished in IL-36R-deficient mice19,25. Here, TLR7 is linked to psoriasis.